- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
RCS - Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS
AnnouncementREG - AstraZeneca PLC - Koselugo recommended for EU approval
AnnouncementREG - AstraZeneca PLC - Tezspire Recommended for Approval in EU for CRSwNP
AnnouncementREG - AstraZeneca PLC - Saphnelo met primary endpoint in TULIP-SC
AnnouncementREG - AstraZeneca PLC - Update on RESOLUTE Phase III trial
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - H1 and Q2 2025 results
AnnouncementREG - AstraZeneca PLC - Gefurulimab nanobody met Phase III endpoints
AnnouncementREG - AstraZeneca PLC - AstraZeneca plans to invest $50bn in the US
AnnouncementREG - AstraZeneca PLC - Update on anselamimab in AL amyloidosis
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpt in BaxHTN PhIII trial
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the EU for bladder cancer
Announcement